A Senator Tries to Get Some Basic Questions Answered from FDA, Pfizer & BioNTech

This past week a U.S. Senator critical of the COVID-19 vaccine mandates sought further transparency into the decisions behind the U.S. Food and Drug Administration’s (FDA) unorthodox decision to both maintain the emergency use authorization (EUA) for Pfizer’s BNT-162b2 while at the same time issue a formal approval for BioNTech Comirnaty. TrialSite reported on this quite unusual situation, speculating that this approach was meant to justify what many consider draconian and illegal vaccine mandates. Although no Comirnaty supply would show up in America for some time, the legal framework was in place to force vaccinations with the still emergency use authorized product—hence our title “Games Regulators & Lawyers Play as Pfizer FDA authorization Not Fully that.” We asked a few questions back on August 24, including Why are growing mandates necessary if herd immunity is impossible via vaccination? Secondly, what’s the plan for boosters after eight months? Third, what happens with the next variant? Other considerations involve liability concerns as even though the FDA “approved” Comirnaty, the PREP Act ensures no liability for any patient or consumer. Pfizer, of course, forecasts $...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee